Costs of Rheumatoid Arthritis in a Balkan Country (Serbia)

Janković, Slobodan; Kostić, Marina; Radosavljević, Marija; Jovanović, Snežana

doi:10.1177/0888325408327848

Cited by 4 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The published literature on the costs of RA in the CEE region does not give a clear picture, as studies were performed in only 2 countries (Hungary and Serbia) [5,6]. Moreover, published studies are not consistent in their approach, samples, and data included in the analysis.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries

Orlewska

Ancuta²,

Anić

et al. 2011

Med Sci Monit

View full text Add to dashboard Cite

SummaryBackgroundThe aim of this study was to assess and compare patients’ access to biologic anti-RA drugs in selected Central and Eastern European (CEE) countries and to analyze the determinants of differences between countries.Material/MethodsThis is a multi-country survey study, based on a combination of desk research and direct contact with national RA stakeholders. Data was collected using a pre-defined questionnaire. Affordability was measured using an affordability index, calculated comparing the index of health care expenditures to the price index, using Poland as an index of 1.ResultsThe percentage of patients on biologic treatment in 2009 was highest in Hungary (5% RA patients on biologic treatment), followed by Slovenia (4.5%), Slovakia (3.5%), Czech Republic (2.92%), Romania (2.2%), Estonia (1.8%), and Croatia, Serbia, Poland (below 1.5%). Infliximab, etanercept, adalimumab and rituximab were included in the reimbursement system in all countries, but abatacept and tocilizumab were included only in Slovakia. In Slovenia, public payer covered 75% of the price, and 25% is covered by supplementary health insurance; in Bulgaria public payer covered 50% of etanercept and adalimumab costs, and 75% of rituximab cost. In other countries, biologic drugs are reimbursed at 100%. Affordability index for biologic drugs was the lowest in Slovenia (0.4). In each country national guidelines define which patients are eligible for biologic treatment. Disease Activity Score (DAS28) of over 5.1 and failure of 2 or more disease-modifying anti-RA drugs, including methotrexate, are commonly used criteria.ConclusionsThe most important factors limiting access to biologic anti-RA treatment in the CEE region are macroeconomic conditions and restrictive treatment guidelines.

show abstract

Section: Resultsmentioning

confidence: 99%

“…A Serbian study [6] provided only direct cost data – RA-related health care services, materials and prescription consumed by 12 patients during 1 year (2008). All patients were female, 45–63 years old (mean 52.3), with disease duration of mean 7.4±1.9 years; no patients received biological therapy.…”

Section: Resultsmentioning

confidence: 99%

Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries

Orlewska

Ancuta²,

Anić

et al. 2011

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“…In the Serbian economic environment, pharmacoeconomical evaluations of fidaxomicin or other new drugs are "blurred," with unrealistically low prices of health care services (controlled by the RIHI) in comparison with other health insurance systems in the region [32][33][34].…”

Section: Discussionmentioning

confidence: 99%

Cost-Effectiveness Comparison of Fidaxomicin and Vancomycin for Treatment of Clostridium difficile Infection: A Markov Model Based on Data from a South West Balkan Country in Socioeconomic Transition

Markovic

Kostić

Iličković

et al. 2014

Value in Health Regional Issues

Self Cite

View full text Add to dashboard Cite

show abstract

“…TNF inhibitors have favorable cost effectiveness ratio in case where threshold was estimated from 50 000 to 100 000 €/ QALY, and if threshold is 35000 €/QALY rituximab was found to be the most cost-effective alternative compared to other biologics among the patients with an insufficient response to TNF inhibitors (95). In our country, socio economic settings are different, the costs of the biological drugs are high as in other countries, while the costs of medical services are signifi-cantly lower than in other countries, which leads that biological drugs, tocilizumab is not cost effective for treatment of RA compared do cDMARD-s (92,93).…”

Section: Review Of Effectiveness Of Different Therapeutic Strategies mentioning

confidence: 81%

Rheumatoid Arthritis: A Novel Approach in Diagnosis and Treatment

Kostić

2018

Serbian Journal of Experimental and Clinical Research

View full text Add to dashboard Cite

show abstract

Costs of Rheumatoid Arthritis in a Balkan Country (Serbia)

Cited by 4 publications

References 4 publications

Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries

Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries

Cost-Effectiveness Comparison of Fidaxomicin and Vancomycin for Treatment of Clostridium difficile Infection: A Markov Model Based on Data from a South West Balkan Country in Socioeconomic Transition

Rheumatoid Arthritis: A Novel Approach in Diagnosis and Treatment

Contact Info

Product

Resources

About